Effect of Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare Resource Utilisation in Patients With Dravet Syndrome, Lennox-Gastaut Syndrome, or Tuberous Sclerosis Complex: Real-World Data from a US Claims Analysis

CBD had demonstrated ASM cycle reduction and polypharmacy benefits in controlled trials, but real-world evidence on the magnitude and sustainability of these effects in routine clinical practice was lacking.

Target RWE researchers analyzed real-world data to estimate the effect of CBD on antiseizure medication cycling, polypharmacy burden, and healthcare resource utilization in epilepsy patients, funded by Jazz Pharmaceuticals.

Establishing that CBD reduces ASM cycling and polypharmacy in real-world practice validates clinical trial findings in a broader patient population, providing Jazz Pharmaceuticals with comparative effectiveness evidence for its CBD post-market strategy.

CBD real-world effectiveness on ASM cycling and polypharmacy for Jazz Pharmaceuticals post-market label strategy, Real-world validation of CBD clinical trial polypharmacy reduction findings